LabCorp Venture Fund
VC Fund
Burlington, United States
LabCorp Venture Fund is a VC fund in Burlington focused on Health Care and Biotechnology. LabCorp Venture Fund invests in early stage private companies operating in current or strategically adjacent spaces and developing novel solutions to important problems in health and healthcare.Investments are typically early stage (Series A or Series B). LabCorp’s typical initial investment is $500K-$2M, reserving up to $5M for follow-oninvestment. LabCorp typically does not lead financing rounds, but prefers to co-invest with an institutional or strategic lead.
- Total investments:
- 26
- Last investment:
- Lead investor:
- 12%
Last updated:
For AI agents: llms.txt
Industries LabCorp Venture Fund invests in
Stages LabCorp Venture Fund invests in
Countries LabCorp Venture Fund invests in
Round sizes
Round size
- Series A
- $8M–$24M
- Series B
- $7.5M–$70M
- Venture - Series Unknown
- $7M–$29M
Investment Focus
Industry
- Health Care 16 (62%)
- Biotechnology 11 (42%)
- Medical 10 (38%)
- Health Diagnostics 7 (27%)
- Medical Device 5 (19%)
Stage
- Series A 6 (23%)
- Series B 5 (19%)
- Venture - Series Unknown 5 (19%)
- Seed 4 (15%)
- Funding Round 3 (12%)
Country
- United States 16 (62%)
- United Kingdom 2 (8%)
- Denmark 1 (4%)
- Argentina 1 (4%)
- Switzerland 1 (4%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
N-Power Medicine
|
N-Power Medicine specializes in drug development and clinical research. | $32M / Series B / Sep 01, 2026 | |
Vitestro
|
Vitestro transform patient care with autonomous blood drawing technology. | $70M / Series B / Mar 10, 2026 | |
Prenosis
|
Prenosis Inc. is a health tech innovator devoted to ushering in a new era of precision diagnostics in acute care using artificial intelligence. Its ImmunixTM precision diagnostics platform leverages machine learning algorithms trained on deep biological data and broad clinical data to more holistically capture and illuminate the complex healthstates of patients. Its proprietary NOSISTM dataset is the largest and fastest growing hybrid biomarker-clinical dataset for sepsis care. The Sepsis ImmunoScoreTM diagnostic on the ImmunixTM platform has the potential to save thousands of lives and billions of dollars in healthcare spending annually. | $20M / Series A / Jan 29, 2026 | |
BIOMAKERS
|
BIOMAKERS is a biotechnology research company that offers molecular testing and genetic diagnosis for patient treatment. | $8M / Series A / Jan 12, 2026 | |
Precede Biosciences
|
Precede Biosciences is breaking down the barriers to precision medicine by redefining what can be gleaned from a simple blood draw. Precede aims to increase drug development success rates and to contribute to a future in which every patient can receive a speedy, minimally invasive diagnosis and therapy tailored to the biology of their condition. | $63.5M / Series B / Jan 12, 2026 | |
IMVARIA
|
imvaria was founded in 2019 by a team of physician-engineers from Stanford and Google, seeking to empower clinicians and improve patient outcomes through the development and application of modern computer science techniques to complex and serious diseases. The company's Digital Biomarker Platform enables non-invasive diagnostic and therapeuticpatient stratification via data science and machine learning.imvaria's lead software effort is assigned FDA's Breakthrough Device Designation. | Venture - Series Unknown / Jan 07, 2026 | |
Cellens
|
Cellens is a medical device company that provides clarity and focus on cancer detection. Cellens is a Tufts University spinoff company dedicated to providing patients and doctors with clarity and confidence through noninvasive cancer screening. It was founded in 2019 and is based in Medford, Massachusetts. | $6.5M / Seed / Dec 23, 2025 | |
Emm
|
Emm is developing the next generation of consumer health tools to manage your health on your terms. We want to empower everyone to change the quality of their life by inherently understanding their health though technology and specialist knowledge. | $8.9M / Seed / Nov 19, 2025 | |
SiteLabs
|
SiteLabs engages in testing platform option that will streamline and automate your testing process workflow. | $2M / Seed / Nov 06, 2025 | |
IgniteData
|
Ignite is the UK’s leading provider of technology-driven Patient Recruitment and Real-World Evidence solutions. | $10.9M / Series A / Aug 14, 2025 | |
| See all 26 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does LabCorp Venture Fund invest in?
LabCorp Venture Fund invests primarily in Health Care, Biotechnology and Medical startups, most often at Series A and Series B stage. Most of the 26 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is LabCorp Venture Fund's check size?
LabCorp Venture Fund typically joins rounds of $8M–$24M at Series A, $7.5M–$70M at Series B and $7M–$29M at Venture - Series Unknown. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds LabCorp Venture Fund participates in.
When did LabCorp Venture Fund last invest?
The most recent investment recorded for LabCorp Venture Fund closed in Sep 2026. Shizune tracks 26 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
